200 related articles for article (PubMed ID: 22691924)
1. Practical management of natural killer/T-cell lymphoma.
Tse E; Kwong YL
Curr Opin Oncol; 2012 Sep; 24(5):480-6. PubMed ID: 22691924
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of natural killer-cell malignancies.
Ishida F; Kwong YL
Expert Rev Hematol; 2010 Oct; 3(5):593-602. PubMed ID: 21083476
[TBL] [Abstract][Full Text] [Related]
3. Extranodal natural killer/T-cell lymphoma: advances in the management.
Jaccard A; Hermine O
Curr Opin Oncol; 2011 Sep; 23(5):429-35. PubMed ID: 21743325
[TBL] [Abstract][Full Text] [Related]
4. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
8. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification in extranodal natural killer/T-cell lymphoma.
Kohrt H; Lee M; Advani R
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1395-405. PubMed ID: 20836675
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L
Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825
[TBL] [Abstract][Full Text] [Related]
11. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.
Tse E; Au-Yeung R; Kwong YL
Expert Rev Hematol; 2019 Nov; 12(11):927-935. PubMed ID: 31487202
[No Abstract] [Full Text] [Related]
13. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
Tse E; Kwong YL
Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
[TBL] [Abstract][Full Text] [Related]
14. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
[TBL] [Abstract][Full Text] [Related]
16. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type.
Liang R
Br J Haematol; 2009 Oct; 147(1):13-21. PubMed ID: 19604234
[TBL] [Abstract][Full Text] [Related]
17. How we treat NK/T-cell lymphomas.
Tse E; Zhao WL; Xiong J; Kwong YL
J Hematol Oncol; 2022 Jun; 15(1):74. PubMed ID: 35659326
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous peripheral T-cell lymphoma of cytotoxic phenotype mimicking extranodal NK/T-cell lymphoma.
Pan ST; Chang WS; Murphy M; Martinez A; Chuang SS
Am J Dermatopathol; 2011 Apr; 33(2):e17-20. PubMed ID: 21252637
[TBL] [Abstract][Full Text] [Related]
20. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
Jaccard A; Petit B; Girault S; Suarez F; Gressin R; Zini JM; Coiteux V; Larroche C; Devidas A; ThiƩblemont C; Gaulard P; Marin B; Gachard N; Bordessoule D; Hermine O
Ann Oncol; 2009 Jan; 20(1):110-6. PubMed ID: 18701429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]